BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34718178)

  • 21. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin.
    Si J; Zhao X; Gao S; Huang D; Sui M
    Int J Pharm; 2019 Sep; 568():118499. PubMed ID: 31299338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
    Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
    Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing of camptothecin: An esterase-activatable prodrug delivered by a self-emulsifying formulation that improves efficacy in colorectal cancer.
    Fang T; Ye Z; Chen X; Wang Y; Wan J; Wang H
    Int J Pharm; 2021 Apr; 599():120399. PubMed ID: 33647408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
    Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
    J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multi-stimuli responsive nanoparticulate SN38 prodrug for cancer chemotherapy.
    Liu X; Huang Q; Yang C; Zhang Q; Chen W; Shen Y; Sui M
    J Mater Chem B; 2017 Jan; 5(4):661-670. PubMed ID: 32263833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
    Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
    Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
    Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
    Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
    Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
    Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
    Maliepaard M; van Gastelen MA; Tohgo A; Hausheer FH; van Waardenburg RC; de Jong LA; Pluim D; Beijnen JH; Schellens JH
    Clin Cancer Res; 2001 Apr; 7(4):935-41. PubMed ID: 11309344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
    Imai Y; Nakane M; Kage K; Tsukahara S; Ishikawa E; Tsuruo T; Miki Y; Sugimoto Y
    Mol Cancer Ther; 2002 Jun; 1(8):611-6. PubMed ID: 12479221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells.
    Zhao D; Wu D; Zhang G; Li Y; Shi W; Zhong B; Yu H
    Mol Biol Rep; 2022 Sep; 49(9):8359-8368. PubMed ID: 35764749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
    Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
    Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y; Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
    Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
    Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
    Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
    Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
    Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
    Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies.
    Wang Y; Xie H; Ying K; Xie B; Chen X; Yang B; Jin J; Wan J; Li T; Han W; Fang S; Wang H
    Biomaterials; 2021 Mar; 270():120705. PubMed ID: 33581609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
    Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
    Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.